Home NK:IO

NK:IO

In operation
Equity Financing
Cancer Immunotherapy Researcher

Basic Information

NK:IO Limited is a biotechnology company developing exceptionally effective off-the-shelf cell therapies for solid tumors. It aims to develop new approaches to natural killer (NK) cell-mediated immunotherapy. The company develops cell therapies and small molecule therapies primarily targeting cancer, enabling doctors to target cancer more effectively.
NK:IO Limited
--
15~50 people
January 01, 2020
info@nk-io.com